Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 18/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 18/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL2812375 | 0.93 | CHRM3 (0.39) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2828684 | 0.84 | CHRM3 (0.39) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2828799 | 0.82 | CHRM2 (0.56) | CHRM3CHRM2CHRM1 | |
| Formic Acid SCHEMBL2814954 | 0.81 | CHRM3 (0.51) | CHRM3CHRM2CHRM1 | |
| Formic Acid SCHEMBL2814946 | 0.77 | CHRM3 (0.43) | CHRM3CHRM2CHRM1 | |
| Formic Acid SCHEMBL2812378 | 0.76 | CHRM3 (0.36) | CHRM3CHRM2CHRM1 | |
| Formic Acid SCHEMBL2812382 | 0.74 | CHRM3 (0.50) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2830629 | 0.69 | CHRM2 (0.67) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2818969 | 0.68 | CHRM2 (0.40) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2830934 | 0.68 | CHRM3 (0.46) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249420-A9 | Process for preparing quinuclidinium carbamate derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-20090198064-A1 | Process for preparing quinuclidinium carbamate derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| EP-1781651-B1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| EP-1781651-A1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006010452-A1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249420-A9 | Process for preparing quinuclidinium carbamate derivatives | CPS1, NAAA, QPCT | CHRM3 549/4885CHRM2 678/4885CHRM1 612/4885 |
| US-20090198064-A1 | Process for preparing quinuclidinium carbamate derivatives | CPS1, NAAA, QPCT | CHRM3 549/4885CHRM2 678/4885CHRM1 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.